KRAS and colorectal cancer: Either way, it underscores that across KRAS-mutant model systems of pancreatic, lung, and colorectal cancer, resistance to dual-mechanism ERK/MAPK inhibition occurs secondary to large-scale transcriptional adaptations which rely on Mediator kinase.